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Background: Malaria transmission in Latin America is generally hypoendemic and unstable, with Plasmodium vivax
as the most prevalent species. However, only a few studies have been carried out in areas with low and unstable
transmission, whereas the clinical profile of malaria has been broadly described in hyperendemic areas. The pattern
of clinical manifestations and laboratory findings in low to moderate endemic areas of Colombia is reported here.
Methods: A passive surveillance study was conducted between 2011 and 2013 involving 1,328 patients with
Plasmodium falciparum, P. vivax or mixed malaria infections attending malaria points-of-care of four malaria
endemic-areas with distinct transmission intensities and parasite distribution. Trained physicians recorded clinical
symptoms and signs as well as socio-demographic characteristics of study participants. Haematological, biochemical
and urine tests were performed at the time of diagnosis.
Results: Out of 1,328 cases, 673 (50.7%) were caused by P. vivax; 650 (48.9%) were due to P. falciparum; and five
(0.4%) patients had mixed infections (P. falciparum/P. vivax). Most patients (92.5%) presented with uncomplicated
malaria characterized by fever, chills, headache, sweating, myalgia/arthralgia and parasitaemia ≤ 20,000 parasites/μL.
Fever, tachycardia, pallor and abdominal pain on palpation were more frequent in P. falciparum patients, whereas
mild hepatomegaly and splenomegaly were mostly observed with P. vivax. Non-severe anaemia (Hb 7.0-10.9 g/dL)
was observed in 20% of the subjects, whereas severe anaemia (Hb < 7.0 g/dL) was present in four patients. Half of
the patients presented thrombocytopaenia regardless of parasite species. Leukopaenia, neutrophilia and monocytosis
were frequently observed in patients infected with P. falciparum. Mild-to-moderate biochemical alterations were
present in ~25% of the patients, particularly abnormal bilirubin in those with P. falciparum and abnormal transaminases
in P. vivax malaria patients. Proteinuria was present in ~50% of the patients regardless of parasite species, whereas
haemoglobinuria was more common in P. vivax infections. Only 7.5% of the cases were classified as clinically severe
malaria, caused by both P. vivax and P. falciparum.
Conclusions: The high prevalence of uncomplicated malaria associated with moderate parasitaemia suggests the
importance of timely diagnosis and effective treatment and encourages new activities to further decrease complicated
malaria cases and mortality.
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Malaria remains a major public health problem in the
developing world. In 2013, it caused an estimated 198
million clinical cases and 584,000 deaths [1]. The vast
majority of these cases (80%) and deaths (90%) were caused
by Plasmodium falciparum infections in sub-Saharan
Africa, the region with the highest rates of transmission
worldwide. High frequency of severe disease and fatal
complications occur primarily during infancy and early
childhood in this region [1,2]. Plasmodium vivax is the
second most prevalent species that accounts for 75 to
85 million cases/year, corresponding to >50% of malaria
infections outside of Africa [3]. In Latin America, malaria
transmission is typically classified as hypoendemic and un-
stable (annual parasite incidence, API < 0.1 per 1,000 per
year) for both Plasmodium species, with ~145 million
inhabitants at risk of infection [1,4,5] and ~469,000
cases reported in 2012, equivalent to ~0.3% of the global
burden. A total of 108 deaths reported in the region in
2012 correspond to ~0.02% of the reported fatal malaria
cases worldwide; the Amazon basin generating ~90% of
the malaria cases [1]. Colombia accounts for ~13% of
the malaria cases [1,6], predominantly by P. vivax
(>70%), which co-exists with P. falciparum, with a re-
markably different regional prevalence [6,7]. Such dif-
ferences in prevalence are mainly due to the varied
Duffy antigen expression in these populations [8,9], and
the clinical relapses due to P. vivax hypnozoite activa-
tion [10].
Human malaria has a broad clinical spectrum that in-
cludes asymptomatic infection, uncomplicated malaria,
and complicated and lethal malaria cases [11]. This clin-
ical spectrum depends on the complex interaction be-
tween the parasite, human host and environmental
factors [12]. In temperate and sub-tropical regions of
Asia and Latin America, residents of all ages have low
levels of naturally acquired immunity, and thus typically
present with acute or severe disease to mild and more
chronic infections, particularly in adult men [2,13]. Most
of the studies designed to better understand the associ-
ation of the clinical profile of malaria with the parasite
species have been carried out in areas of high malaria
endemicity in Africa and Asia (e.g. Papua New Guinea
and Indonesia), whereas studies carried out in low-to-
moderate endemic areas around the world, particularly
in Latin America, are scarce. Although Colombia is one
of the major contributors to malarial morbidity and
mortality in the region, limited information about the
clinical profile and malaria severity is available [14-18],
and much is based on retrospective studies of hospital-
ized subjects conducted before 2008 [19-21]. In those
reports, severe anaemia, severe thrombocytopenia and
hepatic failure were the most frequently reported com-
plications [14-18,20,21].During the last decade, Colombia has experienced
a malaria-decreasing trend [1,22], which could be ex-
plained by greater efforts to reduce disease burden, se-
verity and mortality due to extensive use of insecticide
bed-nets, and early diagnosis and prompt treatment. In
addition, the low number of severe cases might also be
due to the introduction of explicit indication of clinical
signs of severe malaria in the Colombian Ministry of
Health and Social Protection (MoH) guidelines [19,23,24].
A recent study reported that at least for the regions
studied, the malaria point-of-care (POC) were all located
within an hour away from the patients households [25],
which greatly contributed to early diagnosis and treatment
with a consequent reduction of complicated cases and
mortality [7,19]. It appears that early consultation reduces
the contact of health care personnel in endemic areas
with severe malaria cases, as most of these are likely to be
treated in larger cities with greater health care infrastruc-
ture. Although this may benefit patients, it also leads to a
dispersion of complicated cases with potential loss of valu-
able epidemiological information to accurately assess risk
factors for morbidity and mortality. This study aimed at
prospectively collecting information on the clinical profile
of malaria from a large number of subjects acutely infec-
ted with P. falciparum and P. vivax residing in some of
the highest malaria transmission regions in Colombia.
Methods
Study design and ethical issues
A passive surveillance study was conducted between
2011 and 2013 in four malaria outpatient clinics located
in areas with distinct transmission intensity and parasite
distribution. A total of 1,328 patients presenting malaria
related symptoms were passively recruited at malaria
POC. One site (Buenaventura) was excluded from the
study since September 2012 because of the relatively low
number of malaria cases. Patients with malaria infections
confirmed by microscopic examination of Giemsa-stained
thick blood smears (TBS) [26], and who received oral and
written information about the study before enrollment,
were asked to provide a written informed consent (IC) or
an informed assent (IA) in the case of children <18 years/
old. Both documents were previously approved by the In-
stitutional Review Board (IRB) affiliated with the MVDC
(Malaria Vaccine and Drug Development Center, CECIV).
A trained physician on the study research staff completed
a standard clinical evaluation of all malaria symptomatic
subjects. The local health provider treated all individuals
as soon as the blood sample was drawn, using the national
protocol for malaria treatment [23]. Patients infected with
P. vivax were treated orally with curative doses of chloro-
quine (25 mg/kg provided in three doses) and primaquine
(0.25 mg/kg daily for 14 days), whereas P. falciparum pa-
tients received artemether plus lumefantrine (six doses
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merical code to simplify data collection and identification.
Study sites
Four defined endemic settings in Colombia were se-
lected because of the relatively high level of malaria
prevalence: Tierralta (Department of Córdoba); Quibdó
(Department of Chocó); Tumaco (Department of Nariño);
and Buenaventura (Department of Valle del Cauca)
(Figure 1). Plasmodium vivax and P. falciparum are
both transmitted in different proportions in these re-
spective regions, which display an unstable endemic
pattern [6,7]. Tierralta has a population of ~90,000
inhabitants with 44.4% living in rural areas. Most of
inhabitants are described as mestizo ethnicity with a
small Amerindian Emberá Katío indigenous commu-
nity. The predominant malaria parasite species in this
region is P. vivax (~85%). Tumaco is a port city situated
in the Pacific Coast close to the Ecuadorian border with
a population of ~160,000 inhabitants, predominantly
Afro-descendants with an Amerindian Awá indigenous
community. The predominant malaria parasite species
in the region is P. falciparum (~79%). Quibdó is situated
on the Pacific Coast of Colombia close to the border
with Panamá, with a population of ~100,000, mainly
Afro-descendants. Most malaria cases in Quibdó are
caused by P. falciparum (~70%). Buenaventura has aFigure 1 Distribution of malaria cases in the study areas. The charts
display the proportion of Plasmodium species per site. P. vivax cases
were more frequent in Tierralta (90%) and Buenaventura (77%),
whereas P. falciparum infections were more prevalent in Quibdó
(66%) and Tumaco (85%).population of 350,000 inhabitants with >90% living in the
urban area. Most of the inhabitants are Afro-descendants
and mestizos; in this site P. vivax is the most prevalent
malaria species (~75%).
Clinical assessment
Patients were classified as uncomplicated or severe mal-
aria cases according to the WHO clinical and laboratory
criteria [27] and the Colombian MoH guidelines [23].
The latter are more conservative in some definitions
based on previous evidence: anaemia (Hb < 7 g/dL in
adults and children), renal dysfunction (serum creatin-
ine > 1.5 mg/dL), severe thrombocytopenia (≤20,000
platelets/μL) and hyperparasitaemia (>50,000 parasites/
μL). Uncomplicated malaria was defined as a clinical
malaria case: symptoms such fever >38°C, headache,
chills and/or malaise and a positive TBS without severity
criteria, regardless of parasite species. Severe malaria
was defined as one or more of the clinical or laboratory
parameters [27,23], regardless of the malaria parasite
species. Clinical and parasitological signs of prognostic
danger were recorded [24].
Laboratory tests
Whole blood (7–15 mL) was drawn by venipuncture at
the time of enrollment before anti-malarial treatment.
Samples were collected into Vacutainer tubes containing
either EDTA for plasma collection, or clot activator and
gel for serum separation. Giemsa stained TBS [26] were
examined by a trained malaria microscopists who deter-
mined parasite species and density, which were expressed
in parasites/μL after counting the number of parasites per
200 white blood cells (WBC); counts were normalized
using the actual WBC counts for each patient. For quality
control, 10% of TBS were re-examined by a second micro-
scopist and all samples were confirmed by real-time quan-
titative PCR (RT-qPCR) as described elsewhere [28].
Complete blood cell counts were performed using an
automated haematology analyzer (KX-21 N, Sysmex,
Japan) and both urine dipstick and urine microscopic
analyses were carried out at the local health facility. Sera
for blood chemistry profiles were stored frozen and
analysed using commercial kits at the central Asoclinic
laboratory in Cali (non-endemic area). The following pa-
rameters were measured: haemoglobin (normal values
11.0-16.5 g/dL), haematocrit (normal value 35-50%), cre-
atinine (normal values 0.6-1.1 mg/dL in females, and 0.7-
1.4 mg/dL in males), blood urea nitrogen (BUN; normal
values 7–21 mg/dL), glycaemia (normal values 60–110 mg/
dL), total bilirubin (TB; normal values ≤ l.0 mg/dL), direct
bilirubin (DB; normal values ≤ 0.25 mg/dL), alanine amino-
transferase (ALT; normal values ≤ 31 U/L in females, and ≤
40 U/L in males), aspartate aminotransferase (AST; normal
values ≤ 32U/L in females and ≤ 38U/L in males).
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Study data were collected and managed using REDCap
(Nashville, Tennessee, USA) with electronic data capture
tools [29]. Data were analysed with the statistical soft-
ware MATLAB® 2013a (The MathWorks, Inc., Natick,
Massachusetts, USA). Nominal variables were analysed
using descriptive statistics. The Mann–Whitney U test
was used to compare two groups. Spearman’s rank cor-
relation (rs) was used to assess the correlation between
numeric variables. Chi-square or Fisher’s exact test were
used to compare proportion differences. A p-value < 0.05
was considered statistically significant.
Results
Demographic data and malaria history
A total of 1,328 subjects (55.4% male) with acute malaria
were enrolled in four endemic sites between 2011 and
2013. A total of 563 patients were recruited in Tierralta,
549 in Tumaco, 177 in Quibdó, and 39 in Buenaventura
(Figure 1). Plasmodium species distribution was statisti-
cally different in the study sites; however the overall
distribution indicated a total of 673 (50.7%) participants
presenting with P. vivax malaria, and 650 (48.9%) with
P. falciparum infections. Mixed malaria infections (P.
vivax/P. falciparum) were found in five cases (0.4%); four
in Quibdó and one in Buenaventura.
Patients had a mean age of 26 years (median 21 years;
IQR 14–36 years); children ≤ 15 years of age (25.5%)
were mainly infected with P. vivax, whereas young
adults between 16 and 30 years of age (40.3%) were in-
fected with either P. vivax or P. falciparum (Figure 2).
Some differences in race and occupation were observed
between P. falciparum and P. vivax infected patients.
Tumaco malaria cases were mostly due to P. falciparumFigure 2 Prevalence and parasite species distribution according to
age. Percentage of subjects infected with either P. falciparum or
P. vivax parasites at each stratified age group are shown. Statistical
differences between P. falciparum and P. vivax infections were
calculated using the Chi-square test. *p value < 0.05, **p value < 0.01.where population is mainly Afro-descendent dedicated
to fishing, whereas in Tierralta where population is
mainly mestizo farmers, most cases were induced by
P. vivax (Table 1, Figure 1). Differences in some demo-
graphic and epidemiological variables were observed
between P. falciparum and P. vivax infected patients
(Table 1). Patients presenting mixed infections (n = 5,
3 males) were 8 to 37 years old and reported a median of
8 days of illness (range 3 to 17 days).
Of the entire study population, 677 subjects (51.0%)
self-reported to have experienced previous lifetime mal-
aria episodes with a median of two previous episodes. A
majority of patients (n = 425; 62.8%) reported having suf-
fered malaria within the last six months prior to current
episode, and 6.2% of these during the last month, while
2.3% reported ≥ 10 lifetime episodes.
A total of 359/677 (53%) patients who reported previ-
ous malaria episodes, declared to have received anti-
malarial chemotherapy for the last malaria episode, and
most (~80%) reported taking the complete treatment
regimen. Overall, patients presented at health facilities
promptly for malaria diagnosis regardless of parasite spe-
cies, although a few patients (n = 42) reported >15 days of
illness. A low proportion of patients (n = 77) self-reported
concomitant clinical entities such as chronic cardiovas-
cular diseases (20/77), gastrointestinal disorders (13/77),
chronic respiratory diseases (11/77), diabetes (2/77) and
others.
Most patients (97%) presented with low-to-moderate
parasitaemia (≤20,000 parasites/μL), with the median
parasitaemia significantly higher for P. vivax (3,314 para-




A total of 1,229 individuals (92.5%) were classified as un-
complicated malaria, and >90% reported with the classical
malaria triad of fever, chills and sweating, together with
headache (Table 2, Figure 3). Overall, symptoms pre-
sented with a similar distribution for both parasite species
(Figure 3A). Most frequent clinical signs on physical
examination are shown in Figure 3B. Fever (axillary
temperature >38°C) was significantly more frequent in
P. falciparum cases, whereas pallor was more frequent
in P. vivax infected patients (Figure 3B). Uncommon
symptoms, such as vomiting (23%), cough (15%) and
diarrhea (8%), were mostly reported in P. vivax patients.
Hyperpyrexia (8.1%) and hypothermia (1.3%) were also
observed. Ten patients presented with hepatosplenome-
galy (ranged 1–3 cm below the costal margin) all with
P. vivax infections; one had a mixed infection. None pre-
sented with hepatic dysfunction, although mild alterations
in total bilirubin and hepatic enzymes were observed.
Table 1 Demographic data and malaria history per parasite species
P. falciparum (n = 650) P. vivax (n = 673) p valueb
Median IQRa Median IQR
Age (years) 24 16-38 19 12-33 <0.001
Time of residence (years) 4 1-4 4 3-4 0.365
Previous malaria episodes 2 1-3 3 1-5 <0.001
Days of illness 4 2-6 4 3-5 0.689
Frequencies n % n % p valuec
Male 334 51.4 399 59.3 0.004
Race
Afro-descendant 526 80.9 230 34.2 <0.001
Mestizo 91 14.0 415 61.7 <0.001
Indigenous 28 4.3 22 3.3 0.322
Occupation
Student 237 36.5 226 33.6 0.272
Housewife 177 27.2 150 22.3 0.037
Farmer 47 7.2 141 21.0 <0.001
Otherd 189 29.1 155 23 0.251
Previous malaria episodes (YES) 222 34.2 452 67.2 <0.001
Malaria episodes in the last year 65 29.2 232 51.3 <0.001
Anti-malarial treatmente 43 19.4 314 69.5 <0.001
aIQR: interquartile range. bp value using Mann–Whitney test between P. falciparum and P. vivax. cp value using the Chi-square test between P. falciparum and
P. vivax. dfisherman, miner, timber exploitation, other. etreatment for the last malaria episode. Most frequent and significant data are highlighted in bold.
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Thrombocytopenia was rather common (48.6%) al-
though in most cases it was mild-to-moderate (50,000 to
150,000 platelets/μL); only 20 patients (1.5%) had low
platelets levels (13,000 to 50,000 platelets/μL), with a
negative correlation between platelets count and parasit-
aemia (rs = −0.167; p < 0.0001). Anaemia presented in 19.7%
of patients, mostly ≤ 15 years of age (60.1%; p < 0.0001) with
only three patients (0.2%) displaying severe anaemia. Nei-
ther thrombocytopenia nor anaemia was associated with
parasite species, and more patients infected with P. vivax
had lower erythrocyte mean corpuscular volumes (16.3%
vs 9.9%) and mean corpuscular haemoglobin concentra-
tion (54.0% vs 6.9%) than those infected with P. falcip-
arum. Leukocyte alterations, including leukopaenia








ap value using the Chi-square test between P. falciparum and P. vivax.were more common in P. falciparum infections (p < 0.01)
and displayed a positive correlation between leukocyte
count and parasitaemia (rs = 0.348; p < 0.0001), but none
presented with severe deviations.
Clinical biochemical findings
Blood chemistry parameters of hepatic and renal function
were normal in >60% of the patients. Mild-to-moderate
alterations in bilirubin levels [TB (11%), DB (16%)] were
found mainly in patients infected with P. vivax (p < 0.01),
with a positive correlation between TB levels and para-
sitaemia (rs = 0.155; p < 0.0001). In contrast, abnormal
transaminases (ALT and AST) from mild-to-moderate
levels were more frequent in P. falciparum patients than
P. vivax (14% vs 8%; p < 0.05) (Table 3). Renal function pa-
rameters showed mild alterations in creatinine (26%) andn = 650 P. vivax n = 673 p valuea
% n %
81.4 566 84.1 0.191
10.5 61 9.1 0.392
6.6 42 6.2 0.781
1.5 4 0.6 0.093
Figure 3 Frequency of symptoms and signs associated with P. falciparum and P. vivax infections in the study population. Data shown are the
percentages of malaria patients that reported every symptom (A) or presented with the listed signs (B). All patients reported more than one
symptom or had more than one sign. Statistical differences between P. falciparum and P. vivax infections were calculated using the Chi-square test.
*p value < 0.05, **p value < 0.01.
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species. Proteinuria was observed in 54% P. falciparum
patients and 47% with P. vivax (p = 0.014), and it was
associated with creatinine levels >1.5 mg/dL (p = 0.013).
Other significant alterations more frequently found in P.
falciparum than in P. vivax-infected patients (p < 0.001),
were haematuria (26% vs 4%), ketonuria (22% vs 12%) and
leukocyturia (17% vs 4%), respectively. In contrast, hae-
moglobinuria was more frequently observed in P. vivax
infections (14% vs 4%; p < 0.001). Hypoglycaemia, ranging
between 46 and 59 g/dL was found only in four patients.
Malaria with warning signs
A total of 129/1,323 patients (9.8%), excluding five with
mixed infections, presented with one or more signs
suggesting severe malaria development [24] (Table 4).
Tachypnea in absence of fever was the most frequent.
Twenty-four patients (1.8%) presented with persistent
vomiting (range 5 to 15 episodes), and six presented
with signs of dehydration. Few patients (14/1,323) hadTable 3 Clinical laboratory parameters
Laboratory parameters Uncomplicated malaria (n = 1225)
Median (IQRa)
P. falciparum P. vivax
Haemoglobin (g/dL) 12.5 (11.2-13.6) 12.7 (11.3-14)
Platelets count (x103/μL) 159 (123.5-209) 150 (112–196.5)
Total bilirubin (mg/dL) 0.6 (0.3-0.9) 0.7 (0.4-1.1)
Direct bilirubin (mg/dL) 0.17 (0.08-0.27) 0.18 (0.10-0.32)
ALT (U/L) 33 (24–48) 29 (23–38)
AST (U/L) 21 (14–32) 17 (12–24)
Creatinine (mg/dL) 1.0 (0.9-1.2) 0.9 (0.8-1.1)
aIQR, interquartile range; ALT, Alanine aminotransferase; AST, aspartate aminotransf
P. falciparum and P. vivax. Most frequent and significant data are highlighted in bolconsciousness alteration including somnolence (11/14),
lethargy or irritability and aggressiveness (3/14). A child
(12 years old) presented with only one episode of gener-
alized seizures (<1 min) without any other complication
related to cerebral malaria.
Choluria (bilirubin in urine) was associated with P.
falciparum infection, microscopic haemoglobinuria (Hb-
positive dipstick) and proteinuria (p < 0.010), suggesting
an important renal involvement. Microscopic haematuria
(>3 RBC) and hyperbilirubinaemia (TB >3 mg/dL) were
also observed in 28% and 12% of patients, respectively,
with choluria.
Severe malaria
A total of 99 patients (57% male) with a mean age of
27 years (median 23 years; IQR 15–38 years) were classi-
fied with complicated malaria (Table 5). Fifty-four (4.1%)
of which required hospitalization because of their clin-
ical condition. Thirteen of these patients presented
with two complications simultaneously, one of whichp valueb Severe malaria (n = 99) p valueb
Median (IQRa)
P. falciparum P. vivax
0.024 12.8 (11.5-13.8) 12.8 (10.9-14.2) ns
0.008 120 (83–159) 138 (82–660) ns
<0.001 1.0 (0.3-2.5) 1.0 (0.5-3.4) ns
0.002 0.25 (0.10-0.98) 0.32 (0.18-0.52) ns
<0.001 50 (19–141) 19 (15–38) 0.001
<0.001 75 (32–154) 33 (24–50) 0.001
<0.001 1.0 (0.9-1.3) 1.0 (0.8-1.3) ns
erase; ns, not significant. bp value using the Mann–Whitney test between
d.






n % n %
Tachypnea without fever 17 2.6 30 4.5 0.076
Choluria 30 4.6 13 1.9 0.007
Persistent vomiting 11 1.7 13 1.9 0.744
Consciousness alteration 9 1.4 5 0.8 0.254
Convulsions 1 0.2 0 0 NA
ap value using the Chi-square test. NA, not applicable. Most frequent and
significant data are highlighted in bold.
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one complication (Table 2). The most frequent complica-
tions in patients infected with either P. vivax or P. falcip-
arum were: severe prostration (n = 11), respiratory distress
(n = 4), hyperparasitaemia (n = 4), abnormal spontaneousTable 5 Frequency of complications in malaria patients
Criteria
One complication
Hepatic dysfunction (TB >3 mg/dL)
Hepatic dysfunction (ALT > 120 U/L)




Hyperparasitaemia (>50,000 asexual parasites/μL)
Abnormal spontaneous bleeding
Severe anaemia (Hb < 7 g/dL)
Cardiogenic shock/systolic dysfunction (SBP < 70 mm Hg)
Severe thrombocytopaenia (≤20,000 platelets/μL)















ap value using the Fisher’s exact test. ALT, alanine aminotransferase; BUN, blood ure
systolic blood pressure; TB, total bilirubin. Most frequent and significant data are hibleeding (n = 4), severe anaemia (n = 4), cardiogenic shock
(n = 1), and severe thrombocytopenia (n = 1) as well as
malaria warning signs including tachypnea in absence of
fever and persistent vomiting or diarrhoea. Cerebral mal-
aria was not observed. The remaining 45 patients were di-
agnosed and treated at the POC as uncomplicated malaria
cases; however, when laboratory test were analysed, these
revealed abnormalities indicating hepatic and renal dys-
functions according to the WHO and Colombian MoH
guidelines [23,27]. However, whether some of these cases
were diagnosed as complicated malaria in other health
care institutions after the study enrollment, could not be
confirmed.
Hepatic dysfunction with alteration in hepatic enzymes
was more frequent in P. falciparum infections and obser-
ved only in adults. In contrast, haemoglobinuria detected
by urine dipstick in absence of microscopic haematuriaP. falciparum P. vivax p valuea
n (%) n (%)
43 42
8 (15.1) 12 (26.1) ns
12 (22.6) 2 (4.3) 0.001
7 (13.2) 7 (15.2) ns
6 (11.3) 5 (10.9) ns
1 (1.9) 9 (19.6) 0.005
1 (1.9) 3 (6.5) ns
3 (5.7) 1 (2.2) ns
3 (5.7) 0 (0.0) NA
1 (1.9) 2 (4.3) ns
1 (1.9) 0 (0.0) NA
0 (0.0) 1 (2.2) NA
10 4
2 (3.8) 0 (0.0) NA
1 (1.9) 1 (2.2) ns
1 (1.9) 0 (0.0) NA
1 (1.9) 0 (0.0) NA
1 (1.9) 0 (0.0) NA
0 (0.0) 1 (2.2) NA
2 (3.8) 0 (0.0) NA
1 (2.2) 0 (0.0) NA
1 (1.9) 0 (0.0) NA
0 (0.0) 1 (2.2) NA
1 (1.9) 0 (0.0) NA
a nitrogen; Hb, haemoglobin; NA, not applicable; ns, not significant; SBP,
ghlighted in bold.
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dysfunction following the WHO criteria was not reported,
but 14 patients met the Colombian MOH criteria (serum
creatinine > 1.5 mg/dL). This alteration was more frequent
in adults than children < 15 years of age (18% vs 4%).
In patients with complicated malaria anaemia (23.2%),
leukopenia (32.3%), and thrombocytopenia (64.6%) were
common haematological alterations. Abnormal transami-
nases (ALT and AST) and hyperbilirubinaemia (TB >
1 mg/dL) were also observed in 45.5% and 46.5% of
patients, respectively (Table 2).
Discussion
As expected most malaria cases reported at the study
sites had no clinical complications (92.5%), which appear
to correlate with the relatively low malaria transmission
in the study areas [7], together with the early diagnosis
and prompt treatment recently reported [30]. During the
last decade the MoH has been expending considerable
effort in an attempt to reduce the burden of infection
and to eliminate malaria mortality. Additionally since
2005, the Global Fund for AIDS, tuberculosis and mal-
aria (GFATM) has sponsored reinforcement of control
activities in most endemic areas of Colombia, includ-
ing the three study sites described here. This GFATM
project appears to have significantly contributed to a
reduction in malaria transmission and, therefore, to
the low mortality reported, particularly in areas of
easy access to health care [19,22]. The fact that it
was found that 4.1% (54/1,328) of the malaria cases
attending the POC required hospitalization even though
most (41/54) displayed only a single severity criterion indi-
cates a great underestimation in the number of compli-
cated malaria cases in official reporting. Between 2011 and
2013, a total of 1,322 of the ~172,000 malaria cases (0.8%)
reported in Colombia during that period were classi-
fied as complicated cases; 48 deaths (~0.3 per thousand)
were considered malaria-related (National Surveillance
Service of Colombia, SIVIGILA). This underestima-
tion is also supported by the 45 individuals managed
as uncomplicated malaria at the POC, who were later
found to have clinical laboratory parameters compat-
ible with the severe malaria case definition [23,27].
Patients attending the malaria POC are usually evalu-
ated by community health workers, with low level of
education, supervision and training, especially for clinical
evaluation; whereas in this study a trained physician evalu-
ated all patients.
Likewise, signs associated with severe clinical malaria
emphasized in the MoH guidelines (warning signs) have
significantly contributed to the early identification of po-
tential malaria complications and to a decrease in the risk
of severity and mortality. Warning signs reported here in
129 patients, including choluria, persistent vomiting anddiarrhoea, tachypnea in absence of fever, hyperpyrexia and
others, have been reported in previous clinical studies
conducted in Colombia [16,24,31].
In contrast, in countries with higher malaria transmis-
sion such as Papua New Guinea [32] and Indonesia [33],
the severe malaria incidence of individuals attending
health facilities was 6.2% and 9%, respectively. Studies
about prevalence of severe malaria in Latin America are
scarce and there have been no previous studies for the
identification of severe cases at primary health facilities.
Available information consists only of a series of case re-
ports of hospitalized patients [20,21,34-37]. Interestingly,
there has been a surge in studies reporting the contribu-
tion of P. vivax to severe malaria burden, challenging
the idea that vivax malaria is ‘benign’ and not lethal
[38,39]. Moreover, there have been recent reports on the
role of P. vivax-infected erythrocytes adherence and
pathophysiology of P. vivax [40-42]. In fact, several
P. vivax severe cases there have been reported in
Colombia [21], Brazil [34,35], Perú [36] and Venezuela
[37], in agreement with this study.
Severe anaemia significantly contributes to malaria
mortality [43]. As in previous reports [16,14,44], an-
aemia was only present as mild-to-moderate in ~20% of
the cases, and severe in only four patients. Because there
is an inverse correlation between Hb levels and days of
illness [45], results would support a short duration of in-
fection and possibly the presence of iron deficiency as
previously reported [46]. While most patients had a low-
to-moderate parasitaemia, higher median parasitaemia
was found in P. vivax-infected patients (3,314 parasites/
μL) than in those infected with P. falciparum (1,482 par-
asites/μL). This finding is in agreement with previous
reports in Colombia [16] and may be explained by the
lower age, and consequently less cumulative malaria ex-
posure in the group most infected by P. vivax (children ≤
15 years/old), which had a significantly higher parasit-
aemia than the older age group.
Although thrombocytopaenia has been reported in up to
94% of acute malaria cases, frequently with severe intensity
[47], here it was observed in less than half of the cases, with
levels that did not represent a risk of spontaneous bleeding.
Both thrombocytopaenia and anaemia are multifactorial
but in both cases immunological factors have been consid-
ered important. The presence of anti-platelet antibodies as
well as phagocyte-mediated platelet clearance have been
previously described in Colombia and Brazil [48,49], how-
ever this hypothesis was not tested in this study.
Malaria-induced changes in the leukocyte populations
are very diverse [50-54]; most commonly described al-
terations like mild-to-moderate leukopaenia, neutrophilia
and monocytosis were transiently observed in this study.
Leukocytosis, previously associated with severe disease and
considered of poor prognosis [53], was not reported here.
Arévalo-Herrera et al. Malaria Journal  (2015) 14:154 Page 9 of 11Because a significant proportion of the malaria cases
(40.3%) occurred in the economically active population
(16–30 years of age), and lower prevalence (25.5%) was
found in children ≤ 15 years of age, the selection of the
study populations was not biased and it is speculated
that malaria transmission may occur near to or inside
households and schools where children ≤ 15 years old
spend most of their time. Although adult members of
the family also spend a significant amount of time in the
house and surrounding neighborhood, they did not ap-
pear to greatly contribute to malaria cases in this study,
possibly harboring asymptomatic infections. A recent
study in the same sites has indicated a prevalence of ~6%
of asymptomatic carriers. In addition, semi-immune
young adult volunteers (≥18 years old) from these sites,
when exposed to experimental challenge with infectious
P. vivax sporozoites developed significantly fewer symp-
toms than naïve volunteers [55]. In this context it could
also be hypothesized that the relatively high prevalence of
uncomplicated malaria in this study could be related to a
significant level of clinical immunity, given the long-term
residence of subjects in the endemic area, as was observed
previously in Colombia [55]. In low transmission settings
malaria clinical immunity develops significantly later;
however, the previous study showed that five to 10 years
of exposure at low transmission intensity could induce
significant clinical immunity. In fact, 50% of patients re-
ported living in the study areas >5 years with 51% report-
ing multiple previous malaria episodes. Furthermore, the
almost equal proportion of P. vivax and P. falciparum
cases appears to be due to the fact that most of the po-
pulation where P. vivax is prevalent are mestizos, whereas
P. falciparum was more prevalent in Afro-descendants
with high prevalence of Duffy negative blood group [8,9].
Conclusions
The present study showed a high prevalence of uncom-
plicated malaria together with moderate parasitaemia,
which appear to be associated with low transmission in-
tensity, early diagnosis and effective treatment, as well as
to variable degrees of clinical immunity. Mild-to-moderate
clinical and laboratory alterations specific to each parasite
species were observed. Interestingly, at this transmission
intensity patients infected with either parasite species
appear to have a similar risk of developing the levels of
severe malaria observed. It is likely that in regions with
greater transmission intensity and other socio-economic
conditions and more limited health infrastructure, P. fal-
ciparum patients would progress to severe and lethal cases
at a greater rate as compared to P. vivax [18,35,56]. Here,
no significant differences were observed in clinical and
laboratory parameters for patients infected with either P.
vivax or P. falciparum. A prospective study is currently
ongoing aimed at a more detailed characterization ofmalaria complications in hospitalized patients and associ-
ated factors, which could contribute to improving MoH
policies and strengthening the malaria information system
in Colombia.
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